We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Anpario Plc | LSE:ANP | London | Ordinary Share | GB00B3NWT178 | ORD 23P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.50 | 0.93% | 272.50 | 270.00 | 275.00 | 272.50 | 270.00 | 270.00 | 6,778 | 13:33:35 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pesticides, Agric Chems, Nec | 31M | 2.53M | 0.1053 | 25.88 | 65.44M |
From May 2019 to May 2024
TIDMANP
RNS Number : 7517Z
Anpario PLC
05 September 2018
5 September 2018
Anpario plc (AIM: ANP)
("Anpario" or "the Company")
Anpario plc, the international producer and distributor of natural animal feed additives for animal health, nutrition and biosecurity announces its interim results for the six months to 30 June 2018.
Financial highlights
-- Sales of GBP14.8m (2017: GBP14.8m), excluding currency movements increased by 5%(1) -- 19% advance in profit before tax to GBP2.2m (2017: GBP1.9m) -- 14% uplift in diluted earnings per share to 8.7p (2017: 7.6p) -- 2% improvement in adjusted ebitda(2) to GBP2.7m (2017: GBP2.6m) -- 10% increase in interim dividend of 2.2p per share (2017: 2.0p) -- Cash balances of GBP12.6m at 30 June 2018 (31 December 2017: GBP13.6m)
Operational highlights
-- Strong sales growth in UK, Europe, China and US markets. -- In line with business development strategy:
o Continued investment in routes to market and product development
o New range of feed security products and Omega 3 supplement launched.
o Renewed focus on Latin American aquaculture market delivering benefits.
Peter Lawrence, Chairman, commented:
"Our business development strategy will progressively improve sales and distribution, while control of costs will ensure that they do not move ahead of the growth we achieve. Our strong balance sheet and consistent cash generation provide Anpario with a sound platform from which to make selective earnings enhancing acquisitions and to further invest in new product development for the future. With a favourable foreign exchange environment more likely in the second half year, I look forward to reporting good progress from the above initiatives early next year."
Chairman's statement
Anpario has delivered another sound performance in the six months to 30 June 2018 and made further good progress in its main markets.
The focus on end users and working closely with major partner distributors has helped to increase the proportion of direct business and this has contributed to a further increase in underlying(1) gross margins. The transformation of our sales and distribution channels is still the key focus, with continued investment in regional commercial teams and product development, while managing costs in line with profit growth.
Anpario's consistent cash generation means the Board is pleased to increase the interim dividend by 10% to 2.2p per ordinary share payable on 30 November 2018 to shareholders on the register at close of business on 16 November 2018.
Financial review
Anpario trades in international markets and currency fluctuations are a normal part of its business. We hedge our currency risk as effectively as we can without taking speculative positions. Compared with the prior year, the period under review saw sterling strengthening against the US dollar and that has impacted our reported results but not our underlying performance which has improved.
Sales in the first half were unchanged at GBP14.8m (2017: GBP14.8m) and gross profit was lower at GBP7.0m (2017: GBP7.3m). If foreign exchange movements are stripped out, sales and gross profit growth would have been 5% and 6% respectively. The gross margin was 47.3% (2017: 49.1%), however the underlying(1) result was an increase to 50.0%. This underlying(1) increase reflects the continuation of the margin growth seen in recent years through higher sales volumes directly to end users.
Despite the strategic enhancements made in sales and product development, administrative expenses fell in the period by 7% to GBP4.8m (2017: GBP5.1m). Foreign exchange gains, included in administrative expenses, were GBP0.2m in the period compared to losses of GBP0.4m in 2017.
Adjusted EBITDA(2) was ahead by 2% at GBP2.7m (2017: GBP2.6m). Profit after tax grew by 18% to GBP1.9m (2017: GBP1.6m), there were no exceptional costs during the period (2017: GBP0.3m).
Basic earnings per share increased by 17% to 9.16p (2017: 7.80p) and diluted earnings per share grew by 14% to 8.66p (2017: 7.62p).
Investment in stock levels at subsidiary locations to support direct sales has increased working capital requirements, the balance sheet remains strong and debt free, cash at the period end was GBP12.6m (31 December 2017: GBP13.6m).
Operations
Our operations in the UK and Europe delivered an excellent result with sales growth of 14% compared with the same period last year. The recovery in milk prices helped strengthen demand for Ultrabond and we achieved good sales growth of Optomega Plus, which is our sustainable Omega 3 supplement and helps improve fertility in dairy cows and is also used for enrichment of eggs. Optomega Plus will play an increasingly important role for both these applications in the UK and elsewhere.
Orego-Stim(R) continued to grow its share of the UK market with a number of veterinary organisations recommending it and leading poultry integrators incorporating its use in their production processes. We are working with industry specialists, offering turnkey solutions for the egg laying industry, and have delivered significant benefits to farmers, who are keen to maximise the profitability of their egg laying stock.
The United States increased sales by 8%, an encouraging result as we continue to penetrate this major market. Orego-Stim(R) is now being used by a number of poultry integrators for various applications, including anti-biotic free bird production. It is being evaluated by more poultry and swine customers and veterinary organisations. Our product ranges continue to make progress in the US and we launched Anpro Advance, a superior next generation toxin binder, at the World Pork Exhibition in Des Moines, Iowa in June.
China achieved a 7% increase in sales and continued to focus on Meriden-Stim and our toxin binder range. This result is particularly commendable as pig prices dropped significantly in the first half of the year, partly as a result of over rapid expansion by producers. While progress in China will be affected in the short term by this market contraction, we are already seeing encouraging signs of improvement. In March China's Appeal Court ruled that Anpario is the rightful owner of the Orego-Stim(R) trademark in China. This is a very important and pleasing conclusion to a lengthy legal battle with a competitor and will help build sales of Orego-Stim(R)
A strong performance in Australia helped that region increase sales by 84%. There are a number of local initiatives underway to expand our market share across all species including the pet sector.
In Asia, sales declined by GBP0.5m, this was mainly attributable to our decision to terminate non-core and low margin product sales to the Philippines. Malaysia and South Korea continue to perform strongly and we expect more progress later this year in Thailand, Indonesia and the Philippines. Our local sales teams are working with some large end users in the region where, having overcome some product registrations issues, we are encouraged by the opportunities.
Latin America experienced a disappointing first half. Sales were affected by the economic situation and the strengthening of the US dollar against local currencies, particularly in Brazil, Mexico and Argentina. Despite these challenges, sales of Orego-Stim(R) have been increasing in both the poultry and dairy markets in Brazil. We also achieved our first sales, and started trials with a number of our products, in the aquaculture markets of Ecuador and Brazil. We appointed new distributors in Chile and Peru last year and this has temporarily affected sales as a consequence we have had to re-register a number of products. Business has now started to move ahead with recent orders received and shipped.
Despite continued geopolitical events in the region and an outbreak of avian influenza, our Middle East sales declined by a modest 2%. There were successes selling Salkil, our salmonella inhibitor, direct to end users in Turkey. The introduction of more products from our range should help drive growth in this volatile region.
Innovation and development
As anti-biotic free meat production grows, vaccines and natural feed additives will play an increasingly important role in supporting the effort to reduce drug use. Through extensive trial work, Orego-Stim(R) has already proved its value in coccidial immunity in poultry following vaccination. Further research has started to demonstrate its compatibility with salmonella vaccination in poultry.
Feedback from UK dairy farmers using Optomega Plus, our new Omega 3 product, for fertility, has been very positive. It is also used as a supplement in the egg laying industry to enrich eggs in Omega 3 for human consumption.
This research and development programme is just a small part of the work our technical team is undertaking in order to support the intellectual property inherent in our products.
Outlook
Our business development strategy will progressively improve sales and distribution, while control of costs will ensure that they do not move ahead of the growth we achieve. Our strong balance sheet and consistent cash generation provide Anpario with a sound platform from which to make selective earnings enhancing acquisitions and to further invest in new product development for the future. With a favourable foreign exchange environment more likely in the second half year, I look forward to reporting good progress from the above initiatives early next year.
Peter Lawrence
Chairman
5 September 2018
1. Underlying growth represents the results for the period adjusted for CER and excluding foreign exchange variances. Constant exchange rates ("CER") growth is calculated by applying the applicable prior period average exchange rates to the Company's actual performance in the respective period.
2. Adjusted EBITDA represents operating profit GBP2.206m (2017: GBP1.860m) adjusted for: share based payments GBP0.112m (2017: GBP0.161m); depreciation, amortisation and impairment charges of GBP0.378m (2017: GBP0.347m) and closure and restructuring costs GBPnil (2017: GBP0.269m).
Unaudited consolidated income statement
for the six months ended 30 June 2018
Hot Features
Premium
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
Notes GBP000 GBP000 GBP000
Revenue 3 14,773 14,803 29,241
Cost of sales (7,779) (7,528) (14,895)
============================== ===== ========== ========== ==========
Gross profit 6,994 7,275 14,346
Administrative expenses (4,788) (5,146) (10,358)
Exceptional items - (269) (627)
============================== ===== ========== ========== ==========
Operating profit 2,206 1,860 3,361
Finance income 35 17 42
============================== ===== ========== ========== ==========
Profit before income tax 2,241 1,877 3,403
Income tax expense (366) (292) (418)
============================== ===== ========== ========== ==========
Profit for the period 1,875 1,585 2,985
Profit attributable to:
Owners of the parent 1,874 1,584 2,985
Non-controlling interests 1 1 -
============================== ===== ========== ========== ==========
Profit for the period 1,875 1,585 2,985
============================== ===== ========== ========== ==========
Basic earnings per share 4 9.16p 7.80p 14.66p
Diluted earnings per share 4 8.66p 7.62p 14.17p
Adjusted earnings per share 4 9.16p 9.13p 16.74p
Diluted adjusted earnings per
share 4 8.66p 8.92p 16.17p
Unaudited consolidated statement of comprehensive income
for the six months ended 30 June 2018
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
GBP000 GBP000 GBP000
Profit for the period 1,875 1,585 2,985
Items that may be subsequently reclassified
to profit or loss:
Exchange difference on translating foreign
operations 76 54 109
Cashflow hedge movements (net of deferred
tax) (107) 162
============================================ ========== ========== ==========
Total comprehensive income for the period 1,844 1,639 3,256
============================================ ========== ========== ==========
Attributable to the owners of the parent: 1,843 1,638 3,256
Non-controlling interests 1 1 -
============================================ ========== ========== ==========
Total comprehensive income for the period 1,844 1,639 3,256
============================================ ========== ========== ==========
Unaudited consolidated statement of financial position
as at 30 June 2018
as at as at as at
30/06/2018 30/06/2017 31/12/2017
Notes GBP000 GBP000 GBP000
Intangible assets 5 10,954 10,851 10,820
Property, plant and equipment 6 3,319 3,442 3,347
Deferred tax assets 451 338 447
================================= ===== ========== ========== ==========
Non-current assets 14,724 14,631 14,614
================================= ===== ========== ========== ==========
Inventories 3,852 2,315 3,088
Trade and other receivables 6,821 6,921 5,720
Derivative financial instruments 76 - 220
Cash and cash equivalents 12,647 12,611 13,559
================================= ===== ========== ========== ==========
Current assets 23,396 21,847 22,587
================================= ===== ========== ========== ==========
Total assets 38,120 36,478 37,201
================================= ===== ========== ========== ==========
Called up share capital 5,357 5,292 5,350
Share premium 10,397 9,518 10,330
Other reserves (5,346) (4,801) (5,406)
Retained earnings 22,123 20,428 20,248
================================= ===== ========== ========== ==========
Equity attributable to owners of
the parent company 32,531 30,437 30,522
Non-controlling interest (1) (1) -
================================= ===== ========== ========== ==========
Total equity 32,530 30,436 30,522
================================= ===== ========== ========== ==========
Deferred tax liabilities 1,045 974 1,044
--------------------------------- ----- ---------- ---------- ----------
Non-current liabilities 1,045 974 1,044
================================= ===== ========== ========== ==========
Trade and other payables 4,149 4,602 5,348
Current income tax liabilities 396 466 287
================================= ===== ========== ========== ==========
Current liabilities 4,545 5,068 5,635
================================= ===== ========== ========== ==========
Total liabilities 5,590 6,042 6,679
================================= ===== ========== ========== ==========
Total equity and liabilities 38,120 36,478 37,201
================================= ===== ========== ========== ==========
Unaudited consolidated statement of changes in equity
for the six months ended 30 June 2018
Called
up
share Share Other Retained Non- controlling Total
capital premium reserves earnings interest equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Balance at 1 January 2017 5,291 9,515 (5,112) 18,843 - 28,537
=================================== ======== ========= ========= ========= ================ =======
Profit for the period - - - 1,585 (1) 1,584
Currency translation differences - - 54 - - 54
Cash flow hedge reserve - - 123 - - 123
=================================== ======== ========= ========= ========= ================ =======
Total comprehensive income for
the period - - 177 1,585 (1) 1,761
=================================== ======== ========= ========= ========= ================ =======
Issue of share capital 1 3 - - - 4
Share-based payment adjustments - - 134 - - 134
=================================== ======== ========= ========= ========= ================ =======
Transactions with owners 1 3 134 - - 138
=================================== ======== ========= ========= ========= ================ =======
Balance at 30 June 2017 5,292 9,518 (4,801) 20,428 (1) 30,436
=================================== ======== ========= ========= ========= ================ =======
Profit for the period - - - 1,400 1 1,401
Currency translation differences - - 55 - - 55
Cash flow hedge reserve - - 39 - - 39
=================================== ======== ========= ========= ========= ================ =======
Total comprehensive income for
the period - - 94 1,400 1 1,495
=================================== ======== ========= ========= ========= ================ =======
Issue of share capital 58 812 - - - 870
Deferred tax regarding share-based payments - - 71 - - 71 Joint share ownership plan - - (825) - - (825) Share-based payment adjustments - - 55 - - 55 Dividends relating to 2016 - - - (1,580) - (1,580) =================================== ======== ========= ========= ========= ================ ======= Transactions with owners 58 812 (699) (1,580) - (1,409) =================================== ======== ========= ========= ========= ================ ======= Balance at 31 December 2017 5,350 10,330 (5,406) 20,248 - 30,522 =================================== ======== ========= ========= ========= ================ ======= Profit for the period - - - 1,875 (1) 1,874 Currency translation differences - - 76 - - 76 Cash flow hedge reserve - - (107) - - (107) =================================== ======== ========= ========= ========= ================ ======= Total comprehensive income for the period - - (31) 1,875 (1) 1,843 =================================== ======== ========= ========= ========= ================ ======= Issue of share capital 7 67 - - - 74 Share-based payment adjustments - - 91 - - 91 =================================== ======== ========= ========= ========= ================ ======= Transactions with owners 7 67 91 - - 165 =================================== ======== ========= ========= ========= ================ ======= Balance at 30 June 2018 5,357 10,397 (5,346) 22,123 (1) 32,530 =================================== ======== ========= ========= ========= ================ =======
Unaudited consolidated statement of cash flows
for the six months ended 30 June 2018
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
GBP000 GBP000 GBP000
Cash generated from operating activities (229) 2,448 5,583
Income tax paid (257) (73) (349)
=========================================== ============ ============ ============
Net cash generated from operating
activities (486) 2,375 5,234
=========================================== ============ ============ ============
Investment in subsidiary - (514) (514)
Purchases of property, plant and equipment (130) (69) (151)
Proceeds from disposal of property,
plant and equipment - 1 44
Payments to acquire intangible assets (354) (298) (624)
Interest received 35 17 42
=========================================== ============ ============ ============
Net cash used in investing activities (449) (863) (1,203)
=========================================== ============ ============ ============
Joint share ownership plan - - (825)
Proceeds from issuance of shares 74 4 874
Dividend paid to Company's shareholders - - (1,580)
=========================================== ============ ============ ============
Net cash used in financing activities 74 4 (1,531)
=========================================== ============ ============ ============
Net increase in cash and cash equivalents (861) 1,516 2,500
Effect of exchange rate changes (51) (17) (53)
Cash and cash equivalents at the beginning
of the period 13,559 11,112 11,112
=========================================== ============ ============ ============
Cash and cash equivalents at the end
of the period 12,647 12,611 13,559
=========================================== ============ ============ ============
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
GBP000 GBP000 GBP000
Cash generated from operating activities
Profit before income tax 2,241 1,877 3,403
Net finance income (35) (17) (42)
Depreciation, amortisation and impairment 378 348 825
(Profit)/Loss on disposal of property,
plant and equipment - 7 19
Share-based payments 91 134 189
Fair value adjustment to derivatives 37 - (44)
Changes in working capital:
Inventories (783) (38) (855)
Trade and other receivables (1,130) (212) 965
Trade and other payables (1,028) 349 1,123
=========================================== ============ ============ ============
Net cash generated from operating
activities (229) 2,448 5,583
=========================================== ============ ============ ============
Notes to the financial statements
for the six months ended 30 June 2018
1. General information
Anpario plc ("the Company") and its subsidiaries (together "the Group") manufacture and supply high performance natural feed additives for the agricultural market with products to improve the health and output of animals.
The Company is traded on the London Stock Exchange AIM market and is incorporated and domiciled in the UK. The address of the registered office is Manton Wood Enterprise Park, Worksop, Nottinghamshire, S80 2RS.
2. Basis of preparation
The consolidated financial statements comprise the accounts of the Company and its subsidiaries drawn up to 30 June 2018.
The Group has presented its financial statements in accordance with International Reporting Standards ("IFRS's"), as endorsed by the European Union, IFRS IC interpretations and the Companies Act 2006 applicable to companies reporting under IFRS. Full details on the basis of the accounting policies used are set out in the Group's financial statements for the year ended 31 December 2017, which are available on the Company's website at www.anpario.com.
This condensed consolidated interim financial information does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2017 were approved by the Board of Directors on 7 March 2018 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified, did not contain an emphasis of matter paragraph and did not contain any statement under section 498 (2) or (3) of the Companies Act 2006.
The consolidated interim financial information for the period ended 30 June 2018 is neither audited nor reviewed.
3. Segment information
Management has determined the operating segments based on the reports reviewed by the Board that are used to make strategic decisions. The Board considers the business from a geographic perspective. Management considers adjusted EBITDA to assess the performance of the operating segments, which comprises profit before interest, tax, depreciation and amortisation adjusted for share-based payments and exceptional items.
Americas Asia Europe MEA Head Office Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
for the six months ended
30 June 2018
Total segmental revenue 2,678 6,401 6,366 2,068 - 17,513
Inter-segment revenue - - (2,740) - - (2,740)
================================ ========== ====== ======== ====== ============= =======
Revenue from external customers 2,678 6,401 3,626 2,068 - 14,773
================================ ========== ====== ======== ====== ============= =======
Adjusted EBITDA 568 2,118 1,410 645 (2,045) 2,696
-------------------------------- ---------- ------ -------- ------ ------------- -------
Depreciation and amortisation (4) (6) - - (368) (378)
Net finance income - - - 1 34 35
Share-based payments - - - - (112) (112)
Profit before income tax 564 2,112 1,410 646 (2,491) 2,241
Income tax - - - - (366) (366)
================================ ========== ====== ======== ====== ============= =======
Profit for the period 564 2,112 1,410 646 (2,857) 1,875
================================ ========== ====== ======== ====== ============= =======
Total assets 38,120 38,120
================================ ========== ====== ======== ====== ============= =======
Total liabilities (5,590) (5,590)
================================ ========== ====== ======== ====== ============= =======
Americas Asia Europe MEA Head Office Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
for the six months ended
30 June 2017
Total segmental revenue 2,859 6,588 5,124 2,136 - 16,707
Inter-segment revenue - - (1,904) - - (1,904)
================================ ========== ====== ======== ====== ============= =======
Revenue from external customers 2,859 6,588 3,220 2,136 - 14,803
================================ ========== ====== ======== ====== ============= =======
Adjusted EBITDA 994 2,057 1,217 833 (2,464) 2,637
================================ ========== ====== ======== ====== ============= =======
Depreciation and amortisation (7) (4) - - (336) (347)
Net finance income 1 - - 1 15 17
Share-based payments - - - - (161) (161)
Exceptional items - (165) - (19) (85) (269)
-------------------------------- ---------- ------ -------- ------ ------------- -------
Profit before income tax 988 1,888 1,217 815 (3,031) 1,877
Income tax 31 8 - (1) (330) (292)
================================ ========== ====== ======== ====== ============= =======
Profit for the period 1,019 1,896 1,217 814 (3,361) 1,585
================================ ========== ====== ======== ====== ============= =======
Total assets 36,478 36,478
================================ ========== ====== ======== ====== ============= =======
Total liabilities (6,042) (6,042)
================================ ========== ====== ======== ====== ============= =======
Americas Asia Europe MEA Head Office Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
for the year ended 31 Dec
2017
Total segmental revenue 6,013 12,461 10,967 3,984 - 33,425
Inter-segment revenue - - (4,184) - - (4,184)
================================ ========== ====== ======== ====== ============= =======
Revenue from external customers 6,013 12,461 6,783 3,984 - 29,241
================================ ========== ====== ======== ====== ============= =======
Adjusted EBITDA 1,818 3,775 2,641 1,528 (4,690) 5,072
-------------------------------- ---------- ------ -------- ------ ------------- -------
Depreciation and amortisation (13) (10) - - (802) (825)
Net finance (income)/expense 1 1 - 2 38 42
Share-based payments - - - - (259) (259)
Exceptional items (36) (254) (3) (42) (292) (627)
-------------------------------- ---------- ------ -------- ------ ------------- -------
Profit before income tax 1,770 3,512 2,638 1,488 (6,005) 3,403
Income tax 17 (31) - (1) (403) (418)
================================ ========== ====== ======== ====== ============= =======
Profit for the year 1,787 3,481 2,638 1,487 (6,408) 2,985
================================ ========== ====== ======== ====== ============= =======
Total assets 37,201 37,201
================================ ========== ====== ======== ====== ============= =======
Total liabilities (6,679) (6,679)
================================ ========== ====== ======== ====== ============= =======
4. Earnings per share
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
Weighted average number of shares in Issue
(000's) 20,472 20,313 20,361
Adjusted for effects of dilutive potential
Ordinary shares (000's) 1,183 473 709
============================================= ============ ============ ============
Weighted average number for diluted earnings
per share (000's) 21,655 20,786 21,070
============================================= ============ ============ ============
Profit attributable to owners of the Parent
(GBP000's) 1,875 1,585 2,985
============================================= ============ ============ ============
Basic earnings per share 9.16p 7.80p 14.66p
Diluted earnings per share 8.66p 7.62p 14.17p
six months six months year ended
to to
30/06/2018 30/06/2017 31/12/2017
GBP000 GBP000 GBP000
Adjusted profit attributable to owners
of the Parent
Profit attributable to owners of the Parent 1,875 1,585 2,985
Exceptional items (net of tax) - 269 544
Prior year tax adjustments - - (121)
============================================= ============ ============ ============
Adjusted profit attributable to owners
of the Parent 1,875 1,854 3,408
============================================= ============ ============ ============
Adjusted earnings per share 9.16p 9.13p 16.74p
Diluted adjusted earnings per share 8.66p 8.92p 16.17p
5. Intangible assets
Patents,
trademarks Software
Customer and Development and
Goodwill Brands relationships registrations costs Licences Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Cost
====================== ========== ======== =============== ============== ============= ========== =======
As at 1 January 2018 5,960 2,768 786 1,346 2,447 589 13,896
Additions - - - 159 158 37 354
Foreign exchange - - - (1) - - (1)
====================== ========== ======== =============== ============== ============= ========== =======
As at 30 June 2018 5,960 2,768 786 1,504 2,605 626 14,249
====================== ========== ======== =============== ============== ============= ========== =======
Accumulated amortisation/impairment
-------------------------------------------------------------------------------------------------------- =======
As at 1 January 2018 - 310 443 395 1,758 170 3,076
Charge for the period - 42 40 100 - 37 219
As at 30 June 2018 - 352 483 495 1,758 207 3,295
====================== ========== ======== =============== ============== ============= ========== =======
Net book value
---------------------- ---------- -------- --------------- -------------- ------------- ---------- -------
As at 30 June 2018 5,960 2,416 303 1,009 847 419 10,954
====================== ========== ======== =============== ============== ============= ========== =======
As at 1 January 2018 5,960 2,458 343 951 689 419 10,820
====================== ========== ======== =============== ============== ============= ========== =======
6. Tangible assets
Fixtures,
Land and Plant and fittings
buildings machinery and equipment Total
GBP000 GBP000 GBP000 GBP000
Cost
========================= =========== =========== ============== =======
As at 1 January 2018 2,181 2,088 430 4,699
Additions - 97 33 130
Foreign exchange - 1 - 1
========================= =========== =========== ============== =======
As at 30 June 2018 2,181 2,186 463 4,830
========================= =========== =========== ============== =======
Accumulated depreciation
------------------------- ----------- ----------- -------------- -------
As at 1 January 2018 308 776 268 1,352
Charge for the period 16 108 35 159
As at 30 June 2018 324 884 303 1,511
========================= =========== =========== ============== =======
Net book value
------------------------- ----------- ----------- -------------- -------
As at 30 June 2018 1,857 1,302 160 3,319
========================= =========== =========== ============== =======
As at 1 January 2018 1,873 1,312 162 3,347
========================= =========== =========== ============== =======
Enquiries
Anpario plc
Richard Edwards Chief Executive Officer +44(0) 777 6417 129 Karen Prior Finance Director +44(0) 1909 537380
Peel Hunt LLP
Adrian Trimmings, George Sellar +44 (0)207 418 8900
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR DMGGLDDRGRZM
(END) Dow Jones Newswires
September 05, 2018 02:00 ET (06:00 GMT)
1 Year Anpario Chart |
1 Month Anpario Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
